Max Planck Researchers Discover How Sequence Changes Prevent mRNA Errors

Researchers at the Max Planck Institute for Multidisciplinary Sciences discovered why ribosomes slip when reading modified mRNA and how changing specific sequences like UUU C prevents these errors. The findings, published in Nature Communications on October 13, 2026, provide a new rule set for designing safer therapeutics.

Modified mRNA Building Blocks Create Mechanical Vulnerability in Cells

When the coronavirus SARS-CoV-2 disrupted global health, mRNA vaccines delivered a rapid medical breakthrough. Central to current vaccine architecture is the substitution of the natural mRNA building block uridine with a modified version called N1-methylpseudouridine. While this chemical adjustment lowers unwanted immune activation and helps sustain robust protein output, it introduces a mechanical vulnerability inside the cell.

Human cells translate messenger RNA into proteins by reading three genetic letters at a time, with each triplet specifying a single amino acid. When ribosomes encounter N1-methylpseudouridine at specific locations, the modification destabilizes the interaction between the transfer RNA and the mRNA strand. This instability allows the ribosome to slip forward by a single nucleotide, knocking subsequent codons out of alignment and manufacturing unintended proteins with unpredictable cellular properties. Changing the sequence without changing the encoded protein, for example from UUU C to UUC C, almost completely abolished frameshifting.

Max Planck Researchers Discover How Sequence Changes Prevent mRNA Errors — Photo: sciencedirect.com

Max Planck Institute Single-Molecule Findings and Experimental Design

“Our study provides a rule set for designing mRNA vaccines and therapeutics,” Poulis says.

Panagiotis Poulis, Max Planck Institute for Multidisciplinary Sciences

The study pinpointed problematic sequences where the translational machinery stumbles. For instance, the team identified UUU C as a slippery sequence when uridine is replaced by the modified nucleotide.

Codon Sequence Engineering for Future Vaccines and Cancer Immunotherapies

Mitigating translation errors does not require abandoning modified mRNA entirely. Instead, developers can alter the surrounding nucleotide architecture without changing the final amino acid sequence of the encoded protein. Changing a slippery motif from UUU C to UUC C nearly eliminated ribosomal frameshifting in the team’s tests. By avoiding sequences that promote frameshifting, developers can reduce unintended translation products while retaining the benefits of modified mRNA.

This sequence-level correction supplies a concrete rule set for developers working on the next wave of inoculations.

“When selecting modifications for therapeutic mRNAs, we need to consider two things: how effectively they reduce unwanted immune activation and how faithfully the mRNA is translated,” Rodnina explains.

Marina V. Rodnina, Director of the Department of Physical Biochemistry at the Max Planck Institute for Multidisciplinary Sciences

The findings, detailed in Nature Communications under the title Recoding by N1-methylpseudouridine guides rational mRNA vaccine design, bridge a persistent gap between attenuating inflammatory immune responses and maintaining translational fidelity across therapeutic applications.